AstraZeneca PLC
ZEG
Company Profile
Business description
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
E: ir@astrazeneca.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
94,300
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,637.80 | 12.90 | 0.15% |
CAC 40 | 7,779.72 | 8.38 | -0.11% |
DAX 40 | 23,968.30 | 69.89 | -0.29% |
Dow JONES (US) | 42,015.07 | 83.63 | -0.20% |
FTSE 100 | 8,716.45 | 9.56 | -0.11% |
HKSE | 23,573.38 | 315.07 | 1.35% |
NASDAQ | 19,194.91 | 93.97 | 0.49% |
Nikkei 225 | 38,432.98 | 710.58 | 1.88% |
NZX 50 Index | 12,281.31 | 80.95 | -0.65% |
S&P 500 | 5,900.13 | 11.58 | 0.20% |
S&P/ASX 200 | 8,409.80 | 12.90 | 0.15% |
SSE Composite Index | 3,363.45 | 23.51 | 0.70% |